New combo pill shows promise for type 2 diabetes in japanese patients
NCT ID NCT01026194
First seen Jan 06, 2026 · Last updated Jun 22, 2026 · Updated 30 times
Summary
This study tested whether adding teneligliptin to the standard diabetes drug pioglitazone improves blood sugar control in 204 Japanese adults with type 2 diabetes. Participants received either a placebo or teneligliptin for 12 weeks, followed by an open-label extension for up to 52 weeks. The main goal was to measure changes in HbA1c, a key marker of blood sugar control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Study site
Shinjukuku, Tokyo, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Teneligliptin (a DPP-4 inhibitor) combined with pioglitazone (a thiazolidinedione)
What this could lead to
If successful, this combination could offer a new treatment option to help control blood sugar in people with type 2 diabetes who are already on pioglitazone.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all populations. The drug combination may cause side effects like weight gain or fluid retention, and long-term benefits beyond 52 weeks are not proven here.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.